Cantor Fitzgerald Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) but lowers the price target from $37 to $28.
August 07, 2024 | 6:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on ACADIA Pharmaceuticals but lowers the price target from $37 to $28.
The lowered price target from $37 to $28 suggests a less optimistic outlook for ACADIA Pharmaceuticals, which could negatively impact the stock price in the short term despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100